Found 59 matching trials
CPX-351 in Higher Risk Myelodysplastic Syndromes
PHASE1Study of the efficacy of CPX-351 treatment in patients with higher risk mye...
Location
CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
PHASE2Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (B...
Location
Local Institution - 113
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome
PHASE2This is a Phase II study to evaluate the efficacy of second-line lenalidomi...
Location
Ulsan University Hospital
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
PHASE1This is a multicenter, open-label, Phase 1 study to assess the safety and a...
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
PHASE2The main objective of the study is to evaluate the efficacy and safety of m...
Location
Shanghai Jiao Tong University School of Medicine Affilated Shanghai General Hospital
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
PHASE3This is a multicenter, randomized, open-label, pragmatic low intervention c...
Location
University Hospital Brno
Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)
PHASE1This study will evaluate the safety of autologous T cells that have been im...
Location
University of California, San Diego
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
PHASE3The primary objective of this study is to demonstrate the efficacy of Iomab...
Status
Active Not Recruiting
Location
Banner MD Anderson Cancer Center
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
N/AThis is a multicenter, prospective, translational study, to evaluate the im...
Status
Active Not Recruiting
Location
AO Spedali Civili di Brescia
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
PHASE2The main objective of this study was to assess the safety profile of MBG453...
Location
Mayo Clinic Arizona